Objectives: To evaluate the in vitro photodynamic activity of aluminum phthalocyanine tetrasulfonate chloride (AlPc-ClS4 ) on promastigotes and amastigotes of Leishmania (Viannia) peruviana and Leishmania (Viannia) braziliensis. Materials and methods: The activity of photodynamic therapy using AlPcClS4 on Leishmania promastigote and amastigotes was determined by the Methyl Thiazole Tetrazolium (MTT) colorimetric method and quantitative PCR, respectively. Results: Photodynamic treatment showed an inhibitory effect on promastigotes, particularly on Leishmania (V.) pe-ruviana, to a lesser extent on Leishmania (V.) braziliensis and also on intracellular forms of both species. At 24 hours post-radiation, using concentrations of 200 μM and 350 μM, the inhibitory effect on Leishmania (V.) peruviana was 72.9% and 73.9% respectively; at 96 hours the inhibitory effect was of 78.8% and 80.6%, respectively. Regarding intracellular forms, the inhibitory effect on Leishmania (V.) peruviana amastigotes was 57.8% at 72 hours post-treatment, using a concentration of 200 μM. The IC50 was 56.5, 50, 44 and 39.7 μM, at 24, 48, 72 and 96 hours post-radiation, respectively. Conclusions: Photodynamic therapy using AlPcClS4 against Leishmania species showed encouraging results, mainly on Leishmania (V.) peruviana, suggesting a potential use as an alternative or complement to the usual treatment of tegu-mentary leishmaniasis. However, new trials are still required to determine the selectivity index for the intracellular form of the parasite, and to develop methods to facilitate the efficient entry of the molecule into the host cell and the parasite.
|Translated title of the contribution||In vitro inhibitory effect of aluminum phthalocyanine tetrasulfonate chloride against leishmania (Viannia) peruviana and leishmania (viannia) braziliensis|
|Number of pages||9|
|Journal||Revista Peruana de Medicina de Experimental y Salud Publica|
|State||Published - 1 Jul 2020|
Bibliographical noteFunding Information:
Agradecimientos: Al Programa Nacional de Innovaci?n para la Competitividad y Productividad-INNOVATE-PERU (Convenio N.o 177-PNICP-PIAP-2015) por el financiamiento del presente trabajo de investigaci?n. Al Centro Nacional de Salud P?blica del Instituto Nacional de Salud, por las facilidades prestadas. Fuente de financiamiento: El estudio ha sido financiado por el Programa Nacional de Innovaci?n para la Competitividad y Productividad-INNOVATE-PERU (Convenio N.o 177-PNICP-PIAP-2015) del Ministerio de la Producci?n, Lima, Per?.
© 2020, Instituto Nacional de Salud. All rights reserved.